Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

• Institutional investor meetings at Citi’s 14^th Annual Biotech Conference in Boston on September 4, 2019; and
   
• A fireside chat at the Baird 2019 Global Healthcare Conference in New York on September 5, 2019 at 1:25 p.m. ET / 10:25 a.m. PT.

A live audio webcast and replay of the fireside chat will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
[email protected]

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
[email protected]

You May Also Be Interested In

• GFG Closes Private Placement Financing
• ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
• North American Construction Group Ltd. First Quarter Results Conference Call and Webcast Notification